← Product Code [KZE](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/KZE) · K973254 # J-TIP INJECTOR (K973254) _National Medical Products, Inc. · KZE · Nov 24, 1997 · General Hospital · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/KZE/K973254 ## Device Facts - **Applicant:** National Medical Products, Inc. - **Product Code:** [KZE](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/KZE.md) - **Decision Date:** Nov 24, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 880.5430 - **Device Class:** Class 2 - **Review Panel:** General Hospital - **Attributes:** Therapeutic ## Indications for Use Injector used for the Needleless System for the administrations of xylocaine or subcutaneous calcimar/calcitonin which are appropriate for the injection using jet injection or needleless injection systems. The device serves as an alternative to the subcutaneous delivery of xylocaine or calcimar/calcitonin medications with needle and syringe. ## Device Story J-Tip Needleless Injection System; jet injector device; delivers medication subcutaneously without needles. Operates by forcing liquid medication through small orifice at high pressure; creates fine stream penetrating skin. Used as alternative to traditional needle and syringe for xylocaine or calcimar/calcitonin delivery. Operated by healthcare professionals or patients in clinical or home settings. Eliminates needle-stick risks; reduces injection pain/anxiety. Output is subcutaneous medication delivery. ## Clinical Evidence No clinical data provided; substantial equivalence based on technological characteristics and intended use. ## Technological Characteristics Jet injection system; mechanical pressure-based delivery; needleless design; subcutaneous administration; manual operation. ## Regulatory Identification A nonelectrically powered fluid injector is a nonelectrically powered device used by a health care provider to give a hypodermic injection by means of a narrow, high velocity jet of fluid which can penetrate the surface of the skin and deliver the fluid to the body. It may be used for mass inoculations. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized design of three human profiles facing right, connected by a flowing ribbon-like shape. The profiles are silhouetted and overlap each other, creating a sense of unity and connection. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the central design. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 NOV 24 1997 Mr. Danny Patel ·President National Medical Products, Incorporated 57 Parker Street 92718 Irvine, California K973254 Re : J-Tip Needleless Injection System For Trade Name: Subcutaneous Injection of Xylocaine or Calcimar/ Calcitonin Regulatory Class: * II · · Product Code: KZE Dated: August 26, 1997 Received: August 29, 1997 Dear Mr. Patel: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. ਕ substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does ু' {1}------------------------------------------------ Page 2 - Mr. Patel not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to enc regatacion chercred, "hibranding of other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, L. A. Wilmot mothy A. Ulatowski Diredtor Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and_ _ _ _ _ _ _ _ _ Radiological Health Enclosure {2}------------------------------------------------ 1973254 510(k) Number (if known): Device Name: J-Tip Needleless Injection System Indications For Use: Injector used for the Needleless System ਨੇ ਤ The The J-Tip administrations of xylocaine or subcutaneous calcimar/calcitonin which are appropriate for the injection using jet injection or needleless injection systems. For The device serves subcutaneous injections only. 경 동 an xylocaine alternative to the subcutaneous delivery of OL needle calcimar/calcitonin medications with and syringe. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) 1 Patricia Caccavale on Sign-Off) fon of Dental, Infection Control, and General Hospital Devices __ . - -K973254 510(k) Number > Prescription Use_ (Par 21 CFR 801.109) > > . OR Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________ (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/KZE/K973254](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/KZE/K973254) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com